Format
Sort by

Send to

Choose Destination

Search results

Items: 19

1.

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.

Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.

Clin Ther. 2016 Jun;38(6):1288-98. doi: 10.1016/j.clinthera.2016.04.037. Epub 2016 May 19.

PMID:
27210264
3.

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators.

N Engl J Med. 2016 Apr 7;374(14):1321-31. doi: 10.1056/NEJMoa1506930. Epub 2016 Feb 17.

4.

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.

Liu J, Wang LN.

Cochrane Database Syst Rev. 2015 Oct 29;(10):CD010693. doi: 10.1002/14651858.CD010693.pub3. Review.

PMID:
26511368
5.

Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.

Seong JM, Choi NK, Shin JY, Chang Y, Kim YJ, Lee J, Kim JY, Park BJ.

PLoS One. 2015 May 20;10(5):e0124287. doi: 10.1371/journal.pone.0124287. eCollection 2015.

6.

Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.

Viscoli CM, Brass LM, Carolei A, Conwit R, Ford GA, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Lovejoy AM, Parsons MW, Peduzzi PN, Ringleb PA, Schwartz GG, Spence JD, Tanne D, Young LH, Kernan WN; IRIS Trial investigators.

Am Heart J. 2014 Dec;168(6):823-9.e6. doi: 10.1016/j.ahj.2014.07.016. Epub 2014 Jul 28.

7.
8.

Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11.

PMID:
24029780
9.

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.

Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial).

Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):997-1006. doi: 10.1016/j.numecd.2012.09.003. Epub 2012 Oct 11.

PMID:
23063367
10.

Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.

Panicker GK, Karnad DR, Salvi V, Kothari S.

J Assoc Physicians India. 2012 Jan;60:56-61. Review.

PMID:
22715547
11.

Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.

Nagashima A, Watanabe R, Ogawa M, Suzuki J, Masumura M, Hishikari K, Shimizu T, Takayama K, Hirata Y, Nagai R, Isobe M.

J Cardiovasc Pharmacol. 2012 Aug;60(2):158-64. doi: 10.1097/FJC.0b013e3182592d7b.

PMID:
22561360
12.

Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction.

Kataoka Y, Yagi N, Kokubu N, Kasahara Y, Abe M, Otsuka Y.

Circ J. 2011;75(8):1968-74. Epub 2011 Jun 14.

13.

Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway.

Zhang HL, Xu M, Wei C, Qin AP, Liu CF, Hong LZ, Zhao XY, Liu J, Qin ZH.

Neuroscience. 2011 Mar 10;176:381-95. doi: 10.1016/j.neuroscience.2010.12.029. Epub 2010 Dec 24.

PMID:
21185913
14.
15.

Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.

Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK.

Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):437-47. doi: 10.1002/pds.1722.

16.

Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.

Winkelmayer WC, Setoguchi S, Levin R, Solomon DH.

Arch Intern Med. 2008 Nov 24;168(21):2368-75. doi: 10.1001/archinte.168.21.2368.

PMID:
19029503
17.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
18.
19.

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

Nissen SE, Wolski K, Topol EJ.

JAMA. 2005 Nov 23;294(20):2581-6. Epub 2005 Oct 20.

PMID:
16239637
Items per page

Supplemental Content

Loading ...
Write to the Help Desk